Source: Annual Congress 2005 - COPD - treatment III
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
I. V. Litvinova, J. V. Gavrilov, S. I. Ovcharenko, V. A. Sulimov, V. I. Makolkin (Moscow, Russian Federation). Using cardioselective beta-blockers in patients with cardiovascular diseases and COPD. Eur Respir J 2005; 26: Suppl. 49, 1960

Member's Comments

No comment yet.

Related content which might interest you: Using cardioselective beta-blockers in patients with cardiovascular diseases and asthma Source: Eur Respir J 2007; 30: Suppl. 51, 69s Year: 2007 Clinical and inhaled drug profile of COPD patients with indication for beta-blockers who are on beta-blockers Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Is the coprescription of Beta-blockers and Beta2-agonists justified in patients with coexisting COPD and CHF? Source: Annual Congress 2009 - Beta-blockers may now be beneficial in asthma and COPD Year: 2009 Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities Source: Eur Respir Rev, 26 (145) 160123; 10.1183/16000617.0123-2016 Year: 2017 Association of cardiovascular risk with inhaled long-acting anti-muscarinic antagonists in COPD patients with impaired renal function Source: International Congress 2018 – Cardiovascular morbidities in COPD Year: 2018 Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013 Carvedilol, bisoprolol, and metoprolol use in patients with coexistent heart failure and chronic obstructive pulmonary disease: A nationwide population-based study Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events Source: Eur Respir J, 49 (5) 1602245; 10.1183/13993003.02245-2016 Year: 2017 The beta-blockers in combined treatment of coronary heart disease in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2013 –COPD treatment Year: 2013 Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD Source: Eur Respir J 2010; 35: 1003-1021 Year: 2010 Use of metoprolol succinate in patients with cardiovascular diseases associated with asthma or chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 502s Year: 2006 Coexistence of cardiovascular diseases in patients with COPD Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities Year: 2010 Coexisting cardiovascular diseases increase the risk of exacerbations in patients with COPD Source: Annual Congress 2011 - Respiratory epidemiology: comorbidity Year: 2011 Do cardiovascular drugs reduce mortality in patients with COPD in daily practice? A study in primary care Source: Annual Congress 2007 - Management of COPD: pushing forward the boundaries in primary care Year: 2007 Exacerbations and mortality of COPD patients with cardiovascular disease in the UK Source: Annual Congress 2010 - Comorbidity in obstructive airway disease Year: 2010 Effects of cardiovascular agents on respiratory function in COPD patients with concomitant coronary heart disease Source: Eur Respir J 2002; 20: Suppl. 38, 247s Year: 2002 The risk of hyperkalemia in COPD and asthma patients Source: International Congress 2019 – Phenotypes and comorbidities of airway diseases Year: 2019 Beta blocker prescription in patients with coexisting cardiac and obstructive airways disease Source: Eur Respir J 2004; 24: Suppl. 48, 278s Year: 2004 Use of beta-blockers in COPD patients with heart-disease. BBEPOC study Source: Annual Congress 2013 –COPD: markers and inflammation Year: 2013 The impact of cardiovascular drugs in COPD Source: Annual Congress 2011 - Knowing COPD by heart: a relationship beyond comorbidity Year: 2011